posted on 2017-02-07, 06:07authored byJames David McFadyen
Background
Diabetes is a major risk factor for cardiovascular disease,
leading to arterial thrombosis and major vascular events such as ischaemic stroke and myocardial
infarction. While endothelial dysfunction and the associated development of atherosclerotic
lesions are thought to be the primary cause of the adverse effects of diabetes, platelet hyperactivity has also been demonstrated to contribute to the heightened risk of vascular
disease. However, how diabetes influences platelet reactivity, in particular thrombus growth
in vivo, to mediate the prothrombotic phenotype remains poorly understood.
Aims
To investigate the mechanisms by which diabetes results in a
prothrombotic platelet phenotype in vivo.
Key findings
Using a murine model of type 1 diabetes, in conjunction with
distinct in vivo models of thrombosis and endothelial inflammation, as well as high
resolution imaging techniques, the studies in this thesis provide new insights into the
prothrombotic platelet phenotype in diabetes. Diabetic mice exhibit a much shorter time to thrombotic
occlusion following Rose Bengal and ferric chloride induced injury of vessel wall, and a
profoundly enhanced thrombotic response in a rheology-dependent needle insitu model of thrombosis.
Diabetic platelets also display enhanced adhesion to inflamed endothelium induced by
ischaemia or mechanical injury. Surprisingly, this prothrombotic diabetic platelet phenotype
involves the heightened reactivity of platelets in a low activation state, as indicated by their
discoid morphology and lack of P-selectin expression, and is mediated by the elevated adhesive function
of integrin αIIbβ3 under haemodynamic shear. Total internal reflective fluorescent
(TIRF) and scanning electron (SEM) microscopy studies have revealed the existence of a
previously unrecognized membrane structure, termed tractopods, which are αIIbβ3- dependent and
facilitate stable discoid platelet adhesion independently of soluble agonists, and prolong
diabetic platelet adhesion under haemodynamic shear. Examining the underlying mechanisms using
the biomembrane force probe (BFP) system demonstrates a marked elevation in the
biomechanical activation of integrin αIIbβ3 in mouse and human diabetic platelets in a process
linked to a force-induced intermediate conformational change in αIIbβ3 in discoid platelets.
Biochemical analysis of diabetic platelets reveals the differential expression
of proteins involved in PI3K signaling, coupled with the demonstration of enhanced Akt phosphorylation in diabetic
platelets, suggesting that dysregulated PI3K signaling may play an important role in
mediating the prothrombotic diabetic phenotype. In accordance with this, the biomechanical
activation of diabetic αIIbβ3 and the shear dependent prothrombotic diabetic phenotype are exquisitely
sensitive to PI3Kβ deletion and inhibition, but not to the standard antithrombotics, aspirin
and clopidogrel.
Conclusion
The platelet hyperactivity and prothrombotic phenotype seen
in diabetes is linked to the dysregulated biomechanical activation of integrin αIIbβ3 in
discoid platelets. This is facilitated by the formation of a new membrane adhesive structure, termed
tractopods. These processes lead to the marked accumulation of platelets in a low activation
state at sites of thrombus formation and endothelial inflammation in vivo, and is sensitive to PI3Kβ
inhibition but not standard antiplatelet agents. Together, studies in this thesis provide
new insights into the mechanisms underlying the prothrombotic platelet phenotype in diabetes,
and identified PI3Kβ as the potential new target to curb the heightened thrombotic risk
in diabetic patients.